Effect of systemic carnitine therapy on serum fibronectin level in diabetic rats

Basit Öğe Kaydı
dc.authoridAsik, mehmet/0000-0002-0716-0221
dc.contributor.authorKomurcu, Erkam
dc.contributor.authorOzkan, Omer Faruk
dc.contributor.authorKemik, Ahu Sarbay
dc.contributor.authorNusran, Gurdal
dc.contributor.authorAsik, Mehmet
dc.contributor.authorArslan, Emrah
dc.date.accessioned2025-01-27T20:51:58Z
dc.date.available2025-01-27T20:51:58Z
dc.date.issued2014
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractBackground: L-carnitine has been shown to enhance wound healing. There has, however, not been sufficient research on the effect carnitine has on diabetic wound healing. We investigated the relationship between the viability of full thickness skin grafts (FTSGs) and fibronectin (FN) serum levels in diabetic rats that were administered carnitine. Materials and methods: A total of 40 rats were divided into four groups of 10 rats each and operated on. The FTSG model was 10 x 3 cm, with the dorsal flap extending from the tip of the scapula to the hip joint. After surgery, group 1 (nondiabetic control, n = 10) and group 2 (diabetic control, n = 10) were given a sterile saline solution at 0.9% with a dose of 100 mg/kg/d intraperitoneally for 7 d after the surgery. Group 3 (diabetic sham, n = 10) contained diabetic rats and did not receive any agent after the surgery. The diabetic rats in group 4 ( carnitine study diabetic, n 10) were given carnitine with a dose of 100 mg/kg/d intraperitoneally for 7 d after the surgery. Results: The percentages of viable areas in groups 1-4 were 70.38 +/- 6.10%, 62.66 +/- 1.55%, 62.59 +/- 2.94%, and 73.48 +/- 4.43%, respectively. The mean levels of FN, measured in milligram per deciliter, in groupse4 were 23.57 +/- 3.27 mg/dL, 21.58 +/- 2.35 mg/dL, 22.04 +/- 2.71 mg/dL, and 27.11 +/- 2.79 mg/dL, respectively. Furthermore, we found that there was a strong positive correlation (R = 0.509; P = 0.001) between FN and the viability of the FTSG. Conclusions: We demonstrated that administering carnitine leads to an increase in diabetic wound healing. Further increasing the levels of the FNserum might have a role in this process. Crown Copyright (c) 2014 Published by Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.jss.2013.11.1101
dc.identifier.endpage717
dc.identifier.issn0022-4804
dc.identifier.issn1095-8673
dc.identifier.issue2
dc.identifier.pmid24361041
dc.identifier.scopus2-s2.0-84900559494
dc.identifier.scopusqualityQ1
dc.identifier.startpage712
dc.identifier.urihttps://doi.org/10.1016/j.jss.2013.11.1101
dc.identifier.urihttps://hdl.handle.net/20.500.12428/25609
dc.identifier.volume187
dc.identifier.wosWOS:000332770600046
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAcademic Press Inc Elsevier Science
dc.relation.ispartofJournal of Surgical Research
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjectCarnitine
dc.subjectFibronectin
dc.subjectFlap viability
dc.subjectDiabetes mellitus
dc.titleEffect of systemic carnitine therapy on serum fibronectin level in diabetic rats
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu